Business Operations:

Sector: Healthcare
Industry: Biotechnology

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.

Revenue projections:

Investors are expected to be cautious with Regeneron Pharmaceuticals, Inc., as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio	3.335000
forwardPE	12.943378
debtToEquity	8.535000
earningsGrowth	-0.045000
revenueGrowth	0.167000
grossMargins	0.444580
operatingMargins	0.331060
trailingEps	40.430000
forwardEps	60.883640

REGN's current ratio of 3.335, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as REGN has enough cash and current assets to handle its immediate liabilities comfortably.
REGN's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
With positive gross and operating margins, Regeneron Pharmaceuticals, Inc. demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
REGN's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in REGN's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

REGN's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.

Insider Transactions:

13 REGN transactions were recorded, when the market price was 757.6669264573318.The period under consideration saw no sell transactions.Investors have been purchasing Regeneron Pharmaceuticals, Inc. more than selling it at current price levels, which may reflect optimism. This pattern suggests that the market expects favorable outcomes for the stock, leading to increased buying interest.

Recommendation changes over time:

The recent buy bias from analysts suggests REGN is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, REGN appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.